Zacks Investment Research upgraded shares of Nu Skin Enterprises, Inc. (NYSE:NUS) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $70.00 price target on the stock.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Other equities research analysts also recently issued research reports about the stock. Deutsche Bank AG increased their price objective on shares of Nu Skin Enterprises from $63.00 to $66.00 and gave the stock a buy rating in a research report on Wednesday, June 21st. Bank of America Corporation raised their target price on shares of Nu Skin Enterprises from $53.00 to $57.00 and gave the company an underperform rating in a research report on Monday, July 10th. Sidoti downgraded shares of Nu Skin Enterprises from a buy rating to a neutral rating and set a $59.00 target price for the company. in a research report on Wednesday, April 26th. Pivotal Research reaffirmed a buy rating and issued a $65.00 target price on shares of Nu Skin Enterprises in a research report on Thursday, May 4th. Finally, ValuEngine raised shares of Nu Skin Enterprises from a hold rating to a buy rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Nu Skin Enterprises presently has a consensus rating of Hold and an average price target of $62.25.
Shares of Nu Skin Enterprises (NYSE NUS) opened at 62.99 on Wednesday. Nu Skin Enterprises has a 52 week low of $46.35 and a 52 week high of $66.04. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of 20.91 and a beta of 1.31. The firm’s 50 day moving average is $58.20 and its 200-day moving average is $53.72.
Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Wednesday, May 3rd. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.01. Nu Skin Enterprises had a net margin of 7.48% and a return on equity of 23.45%. The company had revenue of $499.10 million during the quarter, compared to the consensus estimate of $493.65 million. During the same quarter in the prior year, the firm earned $0.42 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Equities research analysts predict that Nu Skin Enterprises will post $3.12 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Nu Skin Enterprises, Inc. (NUS) Upgraded to Buy by Zacks Investment Research” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2017/07/18/nu-skin-enterprises-inc-nus-upgraded-to-buy-by-zacks-investment-research.html.
In other Nu Skin Enterprises news, General Counsel D Matthew Dorny sold 8,000 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $56.39, for a total value of $451,120.00. Following the completion of the sale, the general counsel now owns 52,730 shares in the company, valued at $2,973,444.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 24,250 shares of company stock valued at $1,436,770. Corporate insiders own 5.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Nu Skin Enterprises during the fourth quarter worth approximately $3,124,000. State Street Corp boosted its stake in shares of Nu Skin Enterprises by 2.4% in the fourth quarter. State Street Corp now owns 802,056 shares of the company’s stock worth $38,321,000 after buying an additional 18,471 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Nu Skin Enterprises by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 947,226 shares of the company’s stock worth $45,260,000 after buying an additional 39,926 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Nu Skin Enterprises by 269.9% in the fourth quarter. Renaissance Technologies LLC now owns 200,100 shares of the company’s stock worth $9,561,000 after buying an additional 146,000 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its stake in shares of Nu Skin Enterprises by 2.1% in the fourth quarter. New York State Teachers Retirement System now owns 4,900 shares of the company’s stock worth $234,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 85.51% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.